We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
NEJM: oral sunvozertinib reduces the risk of progression by 35% in NSCLC with EGFR exon20ins mutation. Full analysis of efficacy, toxicity and drug availability. Learn more.
